{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T04:24:51Z","timestamp":1727065491039},"reference-count":113,"publisher":"Baishideng Publishing Group Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJSC"],"published-print":{"date-parts":[[2021,6,26]]},"DOI":"10.4252\/wjsc.v13.i6.503","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T14:42:47Z","timestamp":1624545767000},"page":"503-520","source":"Crossref","is-referenced-by-count":4,"title":["Immunotherapy in the treatment of lymphoma"],"prefix":"10.4252","volume":"13","author":[{"given":"Lazar S","family":"Popovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gorana","family":"Matovina-Brko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milica","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Cvetanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Nikolic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biljana","family":"Kukic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragana","family":"Petrovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj996"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/2.suppl_1.57"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm133"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1106536"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114278"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy080"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.136408"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595801"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00814.x"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.610"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000847"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0680"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/35105024"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2365"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0201"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4742"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2617"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.05.001"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.56"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59806"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.84"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-662783"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-770719"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.132761"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-082578"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.598"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651380"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-614636"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.436"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3187"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0451-1"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1159\/000381524"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"B43","unstructured":"Goede V, Fischer K, DyerM, M\u00fclle L, Smolej L, Di Bernardo MC, Knapp A, Nielsen T, Hallek M.   Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. Abstract S151; 2018, 14-17 June, Stockholm, Sweden EHA Congress [Internet]. [cited 15 January 2021] Available from: https:\/\/library.ehaweb.org\/eha\/2018\/stockholm\/215923\/valentin.goede.overall.survival.benefit.of.obinutuzumab.over.rituximab.when.html?f=menu%3D14%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Aspeaker%3D664514"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.3656"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.3402"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy056"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7521"},{"key":"B49","unstructured":"ClinicalTrials gov.   A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND). [accessed January 20, 2021]. In: ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02763319 Clinicaltrials.gov Indentifier: NCT02763319"},{"key":"B50","unstructured":"ClinicalTrials gov.   Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL. [accessed January 21, 2021]. In: ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04134936 Clinicaltrials.gov Identifier: NCT04134936"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.04.011"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807315"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2298\/AOO1301017P"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-861641"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780049"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"B66","unstructured":"ClinicalTrials gov.   A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL). [accessed January 30, 2021]. In ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02611323 ClinicalTrials.gov Identifier: NCT02611323"},{"key":"B67","unstructured":"ClinicalTrials gov.   A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (POLARIX). [accessed 2021 Feb 2]. In ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03274492 ClinicalTrials.gov Identifier: NCT03274492"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0210-1"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0612"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000025"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123742"},{"key":"B73","unstructured":"Dickinson MJ, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martinez-Lopez J, Crump M, Lundberg L, Dixon M, Kwan A, Wei MC, Br\u00f6ske AM, Carlile D, O'Hear C, Hutchings M.   CD20-TCB in relapsed or refractory non-hodgkin lymphoma: durable complete responses and manageable safety observed at clinically relevant doses in phase I dose escalation EHA Meeting 2020; S241 [cited 3 January 2021] Available from: https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/293690\/michael.j.dickinson.cd20-tcb.in.relapsed.or.refractory.non-hodgkin.lymphoma.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122451"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123949"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8005"},{"key":"B87","unstructured":"ClinicalTrials gov.   Immunotherapy (Nivolumab or Brentuximab-Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma. [accessed 2021 Jan 22]. In: ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03907448 ClinicalTrials.gov Identifier: NCT 03907448"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811224"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30221-0"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535443"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01389"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01056"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1568-1"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.11.002"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5415"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127603"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8008"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.5304"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121127"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003618"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001463"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.2298\/MPNS1902025P"},{"key":"B111","unstructured":"ClinicalTrials gov.   Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed\/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7). [accessed January 23, 2021]. In: ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03391466 ClinicalTrials.gov Identifier: NCT03391466"},{"key":"B112","unstructured":"ClinicalTrials gov.   Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA). [accessed January 10, 2021]. In: ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03570892 ClinicalTrials.gov Identifier: NCT03570892"},{"key":"B113","unstructured":"ClinicalTrials gov.   A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM). [accessed January 24, 2021]. In: ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03575351 ClinicalTrials.gov Identifier: NCT03575351"}],"container-title":["World Journal of Stem Cells"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1948-0210\/full\/v13\/i6\/503.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T14:43:03Z","timestamp":1624545783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1948-0210\/full\/v13\/i6\/503.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":113,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.4252\/wjsc.v13.i6.503","relation":{},"ISSN":["1948-0210"],"issn-type":[{"value":"1948-0210","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,26]]}}}